Cristina Mussini
Expertise in
21
conditions

Cristina Mussini

Modena, IT 
Expertise in
21
conditions
Modena, IT 

Overview

Cristina Mussini practices practicing medicine in Modena, Italy.

Ms. Mussini is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, Sepsis, COVID-19, Hepato-Pancreato-Biliary Surgery, and Fasciotomy.

She is actively involved in clinical research, co-authoring 458 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Modena, Italy
Other Locations
Reggio Nell'emilia, Italy
Milan, Italy
Bari, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Current antiretroviral regimen
Study Phase: Phase 3
Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia
Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia
Enrollment Status: Unknown
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drug: Tocilizumab
Study Phase: Phase 2
Strategic Study of Dual-therapy With Darunavir/Ritonavir and Rilpivirine QD Versus Triple-therapy in Patients With Suppressed Viral Load: Virological Efficacy and Evaluation of Non-HIV Related Morbidity.
Strategic Study of Dual-therapy With Darunavir/Ritonavir and Rilpivirine QD Versus Triple-therapy in Patients With Suppressed Viral Load: Virological Efficacy and Evaluation of Non-HIV Related Morbidity.
Enrollment Status: Completed
Publish Date: April 02, 2020
Intervention Type: Drug
Study Phase: Phase 3
Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia - a Randomized Controlled Trial
Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia - a Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: April 09, 2019
Intervention Type: Drug
Study Phase: Not Applicable
View 4 Less Clinical Trials

458 Total Publications

Pre-ART platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio and the risk of non-AIDS-events, AIDS-events and mortality in people with HIV.
Pre-ART platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio and the risk of non-AIDS-events, AIDS-events and mortality in people with HIV.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: May 26, 2026

Frequently Asked Questions about Cristina Mussini

Is Cristina Mussini a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Cristina Mussini is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Cristina Mussini participate in research or clinical trials?

Yes. Cristina Mussini has published 458 articles and abstracts on conditions like HIV/AIDS. You can view a list of Cristina Mussini's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Mussini's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 57 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile